2007 INTERCEPT Conference Abstracts

Societe Francaise d'Hematologie (SFH)
March 22-24, 2007 | Paris, France

• Cognasse F, Osselaer J, Messe N et al.  Cytokines Presentes dans les Concentres Plaquettaires d'Apherese lies aux Reactions Aigues Post-transfusionnelle:  Le Role de sCD40L.
   
• Cognasse F, Osselaer J, Messe N et al.  Liberation des Facteurs Immunomodulateurs des Concentres de Plaquettes au Cours de leur Stockage apres Traitement par Reduction de Pathogenes.

CBS & Héma-Québec Pathogen Inactivation Consensus Conference
March 29-30, 2007 | Toronto, Canada

• Osselaer JC, Doyen C, Chatelain C et al. Impact of Photochemical Treatment (INTERCEPT Blood System for Platelets, IBSP) on Platelet Use in Routine Practice: A Three Year Experience.
  [Poster PDF]
   
• Defoin L, Doyen C, Debry C et al.  Impact of Photochemical Pathogen Inactivation Treatment (INTERCEPT Blood System for Platelets, IBSP) on the Response to Transfusion with 6 and 7- Day Old Components.
  [Poster PDF]
   
• Castro E, Gironés N, Bueno JL et al. The Efficacy of Photochemical Treatment with Amotosalen and UVA (INTERCEPT) for Inactivation of T. cruzi in Buffy Coat Platelet Components.
  [Poster PDF]
   
• Castro E, Bueno JL. Three Years of Routine Use Experience with the INTERCEPT Blood System for Platelets.
  [Poster PDF]
   
• Schlenke P, Hagenah W, Andresen S et al. Platelet Components Treated with Pathogen Inactivation Using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Clinical Trial in Germany.
  [Poster PDF]

International Society for Blood Transfusion (ISBT)
June 24-27, 2007 | Madrid, Spain 

• Garraud O, Fabrigli P, Tardivel R et al. Hemovigilance for Transfusion of INTERCEPT™ Platelets in Routine Therapeutic Use: Experience in Établissement Français du Sang (EFS) Blood Centers.
   
• Cazenave JP, Metzger I, Dréno J et al. Net Cost Impact of Implementation of Photochemical Pathogen Inactivation (INTERCEPT Blood System™ for platelets) for Preparation of Platelet Components.
   
• Isola H, Kientz D, Wiesel ML et al. Implementation of Photochemical Pathogen Inactivation (INTERCEPT Blood System™ for Platelets) in a Regional Blood Center.
  [Poster PDF]
   
• Defoin L, Doyen C, Debry C et al. Impact of Photochemical Pathogen inactivation Treatment (INTERCEPT Blood System™ for Platelets, IBSP) on the Response to Transfusion with 6 and 7-Day Old Components.
  [Poster PDF]
   
• Castro E, Bueno JL, Rodríguez P et al. Three Years of Experience with the INTERCEPT™ Blood System for Apheresis Platelets in Routine Use.
  [Poster PDF]
   
• Schlenke P, Hagenah W, Andresen S et al. Platelet Components Treated with Pathogen Inactivation Using the INTERCEPT™ Blood System: Clinical Outcomes of the First Single-Centre Clinical Trial in Germany.
  [Poster PDF]
   
• Schlenke P, Hagenah W, Andresen S et al. Platelet Concentrates Treated for Pathogen Inactivation Using the INTERCEPT™ Blood System: Manufacturing and Quality Control of INTERCEPT Platelets in Routine.
  [Poster PDF]
   
• Stebler C, Infanti L, Rüesch M et al. A Comparison of Transfusion of Standard and Pathogen Inactivated (INTERCEPT™) Platelets with Regards to CCI and Acute Transfusion Reactions in Hematological Patients.
  [Poster PDF]
   
• Stebler C, Rüesch M, Santoro M et al. Pathogen Inactivation of Double Dose Apheresis Platelets Using the INTERCEPT™ Blood System: Logistical and Financial Cost Benefits and Clinical Efficacy.
  [Poster PDF]
   
• Lambermont G, Cellier N, De Meuter R. One Year of Routine Use of the INTERCEPT Blood System for Platelet Pathogen Inactivation: Product Preparation and Clinical Evaluation.
   
• Cermakova Z, Marcalikova J, Stachelova M. Storage of Apheresis Platelet Concentrates Treated with INTERCEPT System.
   
• Sawyer L, Sampson-Johannes A, Dubensky T et al. Inactivation of Chikungunya Virus in Plasma and Platelets Using the INTERCEPT Blood System™.
  [Poster PDF]
   
• Sawyer L, Corten L, Hanson D et al. Robustness Of Viral Inactivation In High-Dose INTERCEPT Platelets.
  [Poster PDF]
   
• Osselaer JC, Debry C, Goffaux M et al. Coagulation Function in Fresh Frozen Plasma Prepared with Two Photochemical Treatment Methods.
   
• Castro E, Bueno JL, Díaz-Ricart M et al. The Effect of Photochemical Treatment (PCT) with Amotosalen and UVA Light on Coagulation Function of Concurrent Plasma from Platelet Apheresis.
  [Poster PDF]
   
• Cid J, Magallon O, Claparols M et al. Levels Of Coagulation Factors in Fresh Frozen Plasma Obtained from Whole Blood Donations and Prepared with Two Photochemical Treatment Methods.
   
• De Meuter R, Cellier N, Lambermont M.  One Year of Routine Use of the INTERCEPT Blood System for Platelet Pathogen Inactivation:  Product Preparation and Clinical Evaluation.
   
• Kumar V, Pinkowski L, Chapman J et al.  Comparative Study of Fibrin Sealant Prepared from Conventional and INTERCEPT Blood System Plasma Using the Cryoseal FS-System.
   
• North A, Castro G, Erickson A et al.  Characterization of Antibodies to Red Cells Prepared with S-303 Pathogen Inactivation Treatment.
   
• North A, Lee V, Erickson A et al.  Demonstration of an S-303 Induced Immune Response in a Naive Rabbit Model of Chronic Transfusion Using a Sensitive Flow Cytometry Assay.

German Society for Transfusion Medicine and Immunohematology (DGTI)
September 18 –21, 2007 | Friedrichshafen, Germany

• Schlenke P, Hagenah W, Andresen S et al. Pathogen Inactivated Platelets Using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Trial in Germany.  Transfus Med Hemother 2007;34(S1):1-74.

Società Italiana di Medicina Trasfusionale e Immunoematologia (SIMTI)
September 24 –26, 2007 | Stresa, Italy

• Agliastro RE, De Francisci G, Bonaccorso R et al. Report of Four Years of Experience in Production and Clinical Efficacy of Pathogen-Inactivated Platelets.

Japanese Society for Blood Transfusion (JSBT)
October 5–6, 2007 | Takamatsu City, Japan

• Benjamin RJ. The American Red Cross Experience with Bacterial Culture of Platelets: Test Failures Highlight the Need for Robust Pathogen Inactivation Systems.

American Association of Blood Banks Annual Meeting & TXPO (AABB)
October 20 –23, 2007 | Anaheim, California, USA

• Agliastro RE, De Francisci G, Bonaccorso R et al. Report of Four Years of Experience in Production and Clinical Efficacy of Pathogen-Inactivated Platelets.  Transfusion 2007;47 (S3):128A-129A.
   
• Angelini-Tibert MF, Simon P, Currie C et al. Safety of Platelet Components Prepared with Photochemical Treatment Transfused During a Chikungunya Virus Epidemic.  Transfusion 2007;47 (S3):19A-20A.
   
• Angelini-Tibert MF, Currie C, Slaedts M et al. Safety of Platelet Components Prepared with Photochemical Treatment (INTERCEPT) Transfused to Pediatric Oncology-Hematology Patients.  Transfusion 2007;47 (S3):22A.
   
• Brecher ME, Hay SN, Corash LM et al. Evaluation of Bacterial Inactivation in Pre-storage Pooled, Leukoreduced, WB-Derived Platelet Concentrates Suspended in Plasma Prepared with Photochemical Treatment.  Transfusion 2007;47 (S3):130A-131A.
   
• Lam S, Tan HC, Tan LK et al. Efficacy of INTERCEPT Treatment for the Inactivation of Dengue Virus in Single-Donor Platelet Concentrate.  Transfusion 2007;47 (S3):131A-132A.
   
• Osselaer JC, Doyen D, Chatelain C et al. Impact of Pathogen Inactivation (INTERCEPT Blood System) on Platelet Utilization During Three Years of Routine Use.  Transfusion 2007;47 (S3):18A-19A.
   
• Pinkoski L, Corash L. Complement Factors H and I Are Conserved in Plasma After Pathogen Inactivation With Amotosalen and UVA Light. Transfusion 2007;47 (S3):72A.
   
• Rigal D, Merieux Y, Garraud O et al. Conservation of Human Platelet Antigen (HPA) Immunologic Identity After Photochemical Treatment of Platelet Concentrates with Amotosalen (S-59) and UVA Light.  Transfusion 2007;47 (S3):136A.
   
• Roback JD, Isola H, Saakadze N et al. CMV Safety of Platelet Products: Comparison of Inactivation by INTERCEPT Blood System and Removal by Leukofiltration.  Transfusion 2007;47 (S3):23A.
   
• Wagner SJ, Skripchenko A, Myrup A et al. The Effect of Photochemical Treatment (PCT) on the in vitro Properties of Pooled Whole-Blood-Derived Leukoreduced Platelets Stored in 100% Plasma.  Transfusion 2007;47 (S3):129A.

XVIIIth Regional Congress of ISBT, Asia
November 10 - 13, 2007 | Hanoi, Vietnam

• Casenave J.  Models of Increased Safety Measures -- Pathogen Inactivation of Labile Products.

Transfusion Reaction in Patients Foundation (TRIP) Symposium Hemo-en Weefselvigilantie
November 29, 2007 | Utrecht, The Netherlands

• Angelini-Tibert MF, Slaedts M, Irsch J et al. Reduction in Acute Transfusion Reactions in Pediatric Hematology-Oncology Patients Transfused with INTERCEPT Platelets.
   
• Angelini-Tibert MF, Simon P, Slaedts M et al. INTERCEPT Platelets Demonstrate Safety During a Chikungunya Virus Epidemic.
   
• Osselaer JC, Doyen C, Chatelain C et al. Three Years of Experience with the INTERCEPT Blood System (IBS) for Pathogen Inactivation: Impact on Platelet Utilization in a Routine Use Environment.

The American Society of Hematology 49th Annual Meeting and Exposition (ASH)
December 8 –11, 2007 | Atlanta, Georgia 

• Osselaer JC, Doyen C, Graux C et al. Prevention of Transfusion-Associated Graft Versus Host Disease (TA-GVHD) by Photochemical Treatment of Platelet Components: Clinical Experience in Routine Use.  Blood 2007;110(11):849A.
   
• Osselaer JC, Cazenave JP, Waller C et al. An Active Hemovigilance Program Characterizing the Safety Profile of 7,437 Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT).  Blood 2007;110(11):852A.
   
• Roback JD, Isola H, Lin L et al. Inactivation of Infectious CMV in Platelet Products: Comparison of INTERCEPT Blood System and Leukofiltration.  Blood 2007;110(11):849A.
   
• Cazenave JP, Netzer P, Schuhler S et al. Retention of Thrombin Generation Capacity of Therapeutic Apheresis Plasma Prepared with Amotosalen and UVA Light (INTERCEPT) Pathogen Inactivation.  Blood 2007;110(11):75B.